Roche’s satralizumab meets endpoints in inflammatory disorder
admin 2nd December 2019 Uncategorised 0The drug works by targeting the interleukin-6 receptor, a potential key driver of neuromyelitis optica spectrum disorder. More: Roche’s satralizumab meets endpoints in inflammatory disorder Source: News
read more